Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZF2001
- Development stage
- Phase 4
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ZF2001 is a recombinant protein subunit vaccine developed to prevent COVID-19. It consists of a tandem-repeat dimeric receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, produced in Chinese hamster ovary (CHO) cells and formulated with an aluminum hydroxide adjuvant. The vaccine is administered intramuscularly in a three-dose regimen over two months. Clinical trials have demonstrated that it is safe and well tolerated, with phase III data showing an overall efficacy of 82% against symptomatic COVID-19, 93% against the Alpha variant, and 78% against the Delta variant. The vaccine has been approved for use in China, Colombia, Indonesia, and Uzbekistan[1][2][7]. It was developed by Anhui Zhifei Longcom in collaboration with the Chinese Academy of Sciences[1].
- Brand names
- Zifivax
- Other names
- zf2001zf-2001zf 2001ZF-UZ-VAC-2001ZF-UZ-VAC2001ZF-UZ-VAC 2001Zifivax
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on ZF2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZF2001.